Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
StarBio's Tdap is a combination vaccine candidate currently in Phase 2 development for the prevention of tetanus, diphtheria, and pertussis (whooping cough). As a "Tdap" vaccine, it contains a reduced dose of diphtheria toxoid and acellular pertussis antigens compared to the pediatric DTaP vaccine, making it suitable for booster immunization in adolescents and adults. The vaccine works by inducing active immunity through the production of neutralizing antibodies against the toxins produced by *Clostridium tetani* and *Corynebacterium diphtheriae*, as well as specific antigens from *Bordetella pertussis*. The acellular pertussis (aP) component is designed to provide protection with a lower risk of adverse reactions compared to whole-cell pertussis vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tdap.